Skip to main content
. 2019 Feb 1;10:48. doi: 10.3389/fphar.2019.00048

FIGURE 1.

FIGURE 1

CBS alleviates liver injury and reduces serum bile acid levels in rats with 17α-ethinylestradiol-induced cholestasis. (A) Changes in body weight in each group during the six experimental days. Determination of (B) liver weight, (C) liver/body weight, and (D) serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and (E) total bile acid (BA) levels. (F) Hematoxylin and eosin (H&E) staining was used to investigate hepatic structural changes under non-cholestatic and cholestatic conditions in rats. (G) Immunohistochemistry of CK19 was performed to evaluate proliferation of the bile duct. Data are presented as the mean ± SD (n = 6). Significant differences compared with the non-cholestatic group, p < 0.05; ∗∗p < 0.01; compared with the 17α-ethinylestradiol (EE) group, #p < 0.05; ##p < 0.01.